These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18288945)

  • 1. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors.
    Rössler J; Geoerger B; Taylor M; Vassal G
    Curr Cancer Drug Targets; 2008 Feb; 8(1):76-85. PubMed ID: 18288945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
    Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
    Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor tyrosine kinases: the main targets for new anticancer therapy.
    Drevs J; Medinger M; Schmidt-Gersbach C; Weber R; Unger C
    Curr Drug Targets; 2003 Feb; 4(2):113-21. PubMed ID: 12558064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase inhibitors: Are they real tumor killers?
    Gaumann AK; Kiefer F; Alfer J; Lang SA; Geissler EK; Breier G
    Int J Cancer; 2016 Feb; 138(3):540-54. PubMed ID: 25716346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
    Dussault I; Bellon SF
    Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of tyrosine kinase.
    Klohs WD; Fry DW; Kraker AJ
    Curr Opin Oncol; 1997 Nov; 9(6):562-8. PubMed ID: 9370078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
    Yin Y; Yuan X; Gao H; Yang Q
    Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ALK gene, an attractive target for inhibitor development.
    Tartari CJ; Scapozza L; Gambacorti-Passerini C
    Curr Top Med Chem; 2011; 11(11):1406-19. PubMed ID: 21513493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
    Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J; Hochwald SN
    Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for solid tumors: current status.
    Zureikat AH; McKee MD
    Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
    Roussidis AE; Karamanos NK
    In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forthcoming receptor tyrosine kinase inhibitors.
    Choong NW; Cohen EE
    Expert Opin Ther Targets; 2006 Dec; 10(6):793-7. PubMed ID: 17105367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinases and anticancer therapy.
    Medinger M; Drevs J
    Curr Pharm Des; 2005; 11(9):1139-49. PubMed ID: 15853662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
    Mendel DB; Laird AD; Smolich BD; Blake RA; Liang C; Hannah AL; Shaheen RM; Ellis LM; Weitman S; Shawver LK; Cherrington JM
    Anticancer Drug Des; 2000 Feb; 15(1):29-41. PubMed ID: 10888034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
    Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
    Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.